|
1
|
Lacombe C, Da Silva JL, Bruneval P,
Fournier JG, Wendling F, Casadevall N, Camilleri JP, Bariety J,
Varet B and Tambourin P: Peritubular cells are the site of
erythropoietin synthesis in the murine hypoxic kidney. J Clin
Invest. 81:620–623. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Koury ST, Bondurant MC, Semenza GL and
Koury MJ: The use of in situ hybridization to study erythropoietin
gene expression in murine kidney and liver. Microsc Res Tech.
25:29–39. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Frede S, Freitag P, Geuting L, Konietzny R
and Fandrey J: Oxygen-regulated expression of the erythropoietin
gene in the human renal cell line REPC. Blood. 117:4905–4914. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lodish H, Flygare J and Chou S: From stem
cell to erythroblast: Regulation of red cell production at multiple
levels by multiple hormones. IUBMB Life. 62:492–496. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bruno CM, Neri S, Sciacca C, Bertino G, Di
Prima P, Cilio D, Pellicano R, Caruso L and Cristaldi R: Plasma
erythropoietin levels in anaemic and non-anaemic patients with
chronic liver diseases. World J Gastroenterol. 10:1353–1356.
2004.PubMed/NCBI
|
|
6
|
Pinevich AJ and Petersen J: Erythropoietin
therapy in patients with chronic renal failure. West J Med.
157:154–157. 1992.PubMed/NCBI
|
|
7
|
Bohlius J, Weingart O, Trelle S and Engert
A: Cancer-related anemia and recombinant human erythropoietin-an
updated overview. Nat Clin Pract Oncol. 3:152–164. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cella D: The functional assessment of
cancer therapy-anemia (FACT-An) Scale: A new tool for the
assessment of outcomes in cancer anemia and fatigue. Semin Hematol.
34(3 Suppl 2): S13–S19. 1997.
|
|
9
|
Demetri GD, Kris M, Wade J, Degos L and
Cella D: Quality-of-life benefit in chemotherapy patients treated
with epoetin alfa is independent of disease response or tumor type:
Results from a prospective community oncology study. Procrit study
group. J Clin Oncol. 16:3412–3425. 1998.PubMed/NCBI
|
|
10
|
Jeong JY, Hoxhaj G, Socha AL, Sytkowski AJ
and Feldman L: An erythropoietin autocrine/paracrine axis modulates
the growth and survival of human prostate cancer cells. Mol Cancer
Res. 7:1150–1157. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wu P, Zhang N, Wang X, Zhang C, Li T, Ning
X and Gong K: The erythropoietin/erythropoietin receptor signaling
pathway promotes growth and invasion abilities in human renal
carcinoma cells. PLoS One. 7:e451222012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Solár P, Hrčková G, Varinská L, Solárová
Z, Kriška J, Uhrínová I, Kello M, Mojžiš J, Fedoročko P and
Sytkowski AJ: Location and the functionality of erythropoietin
receptor(s) in A2780 cells. Oncol Rep. 28:141–146. 2012.PubMed/NCBI
|
|
13
|
Miyake M, Goodison S, Lawton A, Zhang G,
Gomes-Giacoia E and Rosser CJ: Erythropoietin is a JAK2 and ERK1/2
effector that can promote renal tumor cell proliferation under
hypoxic conditions. J Hematol Oncol. 6:652013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Trost N, Stepisnik T, Berne S, Pucer A,
Petan T, Komel R and Debeljak N: Recombinant human erythropoietin
alters gene expression and stimulates proliferation of MCF-7 breast
cancer cells. Radiol Oncol. 47:382–389. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Abhold E, Rahimy E, Wang-Rodriguez J,
Blair KJ, Yu MA, Brumund KT, Weisman RA and Ongkeko WM: Recombinant
human erythropoietin promotes the acquisition of a malignant
phenotype in head and neck squamous cell carcinoma cell lines in
vitro. BMC Res Notes. 4:5532011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lopez TV, Lappin TR, Maxwell P, Shi Z,
Lopez-Marure R, Aguilar C and Rocha-Zavaleta L: Autocrine/paracrine
erythropoietin signalling promotes JAK/STAT-dependent proliferation
of human cervical cancer cells. Int J Cancer. 129:2566–2576. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Szenajch J, Wcislo G, Jeong JY, Szczylik C
and Feldman L: The role of erythropoietin and its receptor in
growth, survival and therapeutic response of human tumor cells From
clinic to bench-a critical review. Biochim Biophys Acta.
1806:82–95. 2010.PubMed/NCBI
|
|
18
|
Debeljak N, Solár P and Sytkowski AJ:
Erythropoietin and cancer: The unintended consequences of anemia
correction. Front Immunol. 5:5632014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nakamatsu K, Nishimura Y, Suzuki M,
Kanamori S, Maenishi O and Yasuda Y:
Erythropoietin/erythropoietin-receptor system as an angiogenic
factor in chemically induced murine hepatic tumors. Int J Clin
Oncol. 9:184–188. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Okazaki T, Ebihara S, Asada M, Yamanda S,
Niu K and Arai H: Erythropoietin promotes the growth of tumors
lacking its receptor and decreases survival of tumor-bearing mice
by enhancing angiogenesis. Neoplasia. 10:932–939. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Rupertus K, Senger S, Menger MD, Schilling
MK and Kollmar O: Darbepoetin-α promotes neovascularization and
cell proliferation in established colorectal liver metastases. J
Surg Res. 176:517–523. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nico B, Annese T, Guidolin D, Finato N,
Crivellato E and Ribatti D: Epo is involved in angiogenesis in
human glioma. J Neurooncol. 102:51–58. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cao Y, Lathia JD, Eyler CE, Wu Q, Li Z,
Wang H, McLendon RE, Hjelmeland AB and Rich JN: Erythropoietin
receptor signaling through STAT3 is required for glioma stem cell
maintenance. Genes Cancer. 1:50–61. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Todaro M, Turdo A, Bartucci M, Iovino F,
Dattilo R, Biffoni M, Stassi G, Federici G, De Maria R and Zeuner
A: Erythropoietin activates cell survival pathways in breast cancer
stem-like cells to protect them from chemotherapy. Cancer Res.
73:6393–6400. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pérés EA, Valable S, Guillamo JS, Marteau
L, Bernaudin JF, Roussel S, Lechapt-Zalcman E, Bernaudin M and
Petit E: Targeting the erythropoietin receptor on glioma cells
reduces tumour growth. Exp Cell Res. 317:2321–2332. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Akiyama M, Kawano T, Mikami-Terao Y,
Agawa-Ohta M, Yamada O, Ida H and Yamada H: Erythropoietin
activates telomerase through transcriptional and
posttranscriptional regulation in human erythroleukemic JAS-REN-A
cells. Leuk Res. 35:416–418. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Swift S, Ellison AR, Kassner P, McCaffery
I, Rossi J, Sinclair AM, Begley CG and Elliott S: Absence of
functional EpoR expression in human tumor cell lines. Blood.
115:4254–4263. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Elliott S, Swift S, Busse L, Scully S, Van
G, Rossi J and Johnson C: Epo receptors are not detectable in
primary human tumor tissue samples. PLoS One. 8:e680832013.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jadwin JA, Mayer BJ and Machida K:
Detection and quantification of protein-protein interactions by
far-western blotting. Methods Mol Biol. 1312:379–398. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Elliott S, Busse L, McCaffery I, Rossi J,
Sinclair A, Spahr C, Swift S and Begley CG: Identification of a
sensitive anti-erythropoietin receptor monoclonal antibody allows
detection of low levels of EpoR in cells. J Immunol Methods.
352:126–139. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Van Hinsbergh VW, Sprengers ED and
Kooistra T: Effect of thrombin on the production of plasminogen
activators and PA inhibitor-1 by human foreskin microvascular
endothelial cells. Thromb Haemost. 57:148–153. 1987.PubMed/NCBI
|
|
32
|
Defilippi P, van Hinsbergh V, Bertolotto
A, Rossino P, Silengo L and Tarone G: Differential distribution and
modulation of expression of alpha 1/beta 1 integrin on human
endothelial cells. J Cell Biol. 114:855–863. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mlynarcik P, Bencurova E, Madar M, Mucha
R, Pulzova L, Hresko S and Bhide M: Development of simple and rapid
elution methods for proteins from various affinity beads for their
direct MALDI-TOF downstream application. J Proteomics.
75:4529–4535. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bhide MR, Escudero R, Camafeita E, Gil H,
Jado I and Anda P: Complement factor H binding by different Lyme
disease and relapsing fever Borrelia in animals and human. BMC Res
Notes. 2:1342009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Shevchenko A, Tomas H, Havlis J, Olsen JV
and Mann M: In-gel digestion for mass spectrometric
characterization of proteins and proteomes. Nat Protoc.
1:2856–2860. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Till JE and McCulloch E: A direct
measurement of the radiation sensitivity of normal mouse bone
marrow cells. Radiat Res. 14:213–222. 1961. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bonsdorf E and Jalavisto E: A humoral
mechanism in anoxic erythrocytosis. Acta Physiol Scand. 16:150–170.
1948. View Article : Google Scholar
|
|
38
|
Arcasoy MO: The non-haematopoietic
biological effects of erythropoietin. Br J Haematol. 141:14–31.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Arcasoy MO, Jiang X and Haroon ZA:
Expression of erythropoietin receptor splice variants in human
cancer. Biochem Biophys Res Commun. 307:999–1007. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Miller CP, Lowe KA, Valliant-Saunders K,
Kaiser JF, Mattern D, Urban N, Henke M and Blau CA: Evaluating
erythropoietin-associated tumor progression using archival tissues
from a phase III clinical trial. Stem Cells. 27:2353–2361. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Jeong JY, Feldman L, Solar P, Szenajch J
and Sytkowski AJ: Characterization of erythropoietin receptor and
erythropoietin expression and function in human ovarian cancer
cells. Int J Cancer. 122:274–280. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Paragh G, Kumar SM, Rakosy Z, Choi SC, Xu
X and Acs G: RNA interference-mediated inhibition of erythropoietin
receptor expression suppresses tumor growth and invasiveness in
A2780 human ovarian carcinoma cells. Am J Pathol. 174:1504–1514.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ribatti D, Presta M, Vacca A, Ria R,
Giuliani R, Dell'Era P, Nico B, Roncali L and Dammacco F: Human
erythropoietin induces a pro-angiogenic phenotype in cultured
endothelial cells and stimulates neovascularization in vivo. Blood.
93:2627–2636. 1999.PubMed/NCBI
|
|
44
|
Sinclair AM, Coxon A, McCaffery I, Kaufman
S, Paweletz K, Liu L, Busse L, Swift S, Elliott S and Begley CG:
Functional erythropoietin receptor is undetectable in endothelial,
cardiac, neuronal, and renal cells. Blood. 115:4264–4272. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Laugsch M, Metzen E, Svensson T, Depping R
and Jelkmann W: Lack of functional erythropoietin receptors of
cancer cell lines. Int J Cancer. 122:1005–1011. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Vogel V, Kramer HJ, Bäcker A,
Meyer-Lehnert H, Jelkmann W and Fandrey J: Effects of
erythropoietin on endothelin-1 synthesis and the cellular calcium
messenger system in vascular endothelial cells. Am J Hypertens.
10:289–296. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Haller H, Christel C, Dannenberg L, Thiele
P, Lindschau C and Luft FC: Signal transduction of erythropoietin
in endothelial cells. Kidney Int. 50:481–488. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Janmaat ML, Heerkens JL, de Bruin AM,
Klous A, de Waard V and de Vries CJ: Erythropoietin accelerates
smooth muscle cell-rich vascular lesion formation in mice through
endothelial cell activation involving enhanced PDGF-BB release.
Blood. 115:1453–1460. 2010. View Article : Google Scholar : PubMed/NCBI
|
